logo
Securing 74 grants in just two years is a testament to PGI's relentless pursuit of excellence: Dr Rajiv Bahl

Securing 74 grants in just two years is a testament to PGI's relentless pursuit of excellence: Dr Rajiv Bahl

Indian Express16 hours ago
'PGI Chandigarh is truly a national treasure, a hub where the brightest minds converge to push the boundaries of medical science. Over the past two years alone, PGI has secured 74 grants, with nearly half dedicated to developing new interventions and technologies. This is a testament to PGI's relentless pursuit of excellence and its vital role in India's innovation ecosystem,' said Dr Rajiv Bahl, Secretary, Department of Health Research and Director General of the Indian Council of Medical Research.
Addressing the 62nd Institute Foundation Day celebrations of PGI as the chief guest, ICMR director deneral lauded PGI's crucial role in clinical trials and translational research during his keynote address themed on 'Creating more physicians, scientists and innovators in leading medical institutes'. 'PGI's position as one of the primary institutes conducting phase one clinical trials outside industry showcases our capacity to bring cutting-edge therapies from bench to bedside. This is essential for making India a global leader in medical research and development.'
Highlighting the importance of integrating research with clinical practice, Dr Bahl said that the 'future of Indian healthcare rests on our ability to develop new interventions and diagnostic tools. ICMR's focus on evidence-based research, combined with its commitment to training physician scientists, is essential for India's journey toward self-reliance in medical technology'. Dr Bahl emphasised the importance of engineer-doctor industry partnership to create science and research into innovation to reach out to patients as he highlighted 'ICMR's strategic collaborations with IITs, AIIMS, and other premier institutions exemplify our collective commitment to bridging medicine and technology. The pioneering devices developed here, such as the infrared hematoma detector and Mobi-lab, have already garnered international attention, even impressing global leaders like Bill Gates. It's a proud moment for India and a validation of our leadership in healthcare innovation.'
Sharing ICMR's vision for Viksit Bharat, Dr Bahl underpinned that the goal is to support Indian scientists and entrepreneurs in creating first-in-the-world technologies. 'The recent challenge grants and patent support programmes of ICMR are designed to catalyse this spirit of innovation, ensuring India remains at the forefront of medical breakthroughs.'
Earlier, Prof Vivek Lal, Director of PGI, acknowledged the PGI team's diligence and hard work amid an exponentially growing patient burden. 'We make up for infrastructure gaps through relentless passion.'
Thirty-one PGI employees were honoured for their outstanding service on the occasion.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Experts call for inclusion of Chronic Kidney Disease in national NCD programme
Experts call for inclusion of Chronic Kidney Disease in national NCD programme

The Hindu

timean hour ago

  • The Hindu

Experts call for inclusion of Chronic Kidney Disease in national NCD programme

Hyderabad-based dialysis care network, NephroPlus, has urged policymakers to include Chronic Kidney Disease (CKD) screening in India's flagship National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD), as it released a white paper highlighting the rising burden of CKD across India and neighbouring countries. Speaking at a media briefing in Hyderabad on Tuesday, NephroPlus Group CEO Rohit Singh said the findings of the white paper and a large-scale screening initiative make a strong case for integrating CKD testing, particularly serum creatinine and urine albumin-to-creatinine ratio (ACR), into existing government-led screenings for hypertension and diabetes. 'The burden is silent but severe. CKD needs to be part of India's NCD strategy immediately,' he said. The paper is based on data from a kidney health screening campaign conducted in the lead-up to World Kidney Day in March. The campaign spanned 30 locations across India, the Philippines, and Uzbekistan, and covered 12 Indian States. A total of 10,501 persons pledged for kidney health awareness, of whom more than 5,000 underwent free serum creatinine and estimated glomerular filtration rate (eGFR) tests. NephroPlus found that several Indian States reported high prevalence of CKD risk factors. Jharkhand topped the list, followed by Haryana and Uttarakhand, Andhra Pradesh, Bihar, Delhi, Karnataka, Maharashtra, Uttar Pradesh, Telangana, Gujarat and Rajasthan. NephroPlus co-founder Kamal D. Shah stressed the economic and emotional toll of dialysis. 'Dialysis is not just a treatment; it is a lifelong ordeal that drains families physically, emotionally and financially. Our data shows that investing ₹1 in prevention saves ₹10 to ₹15 in future dialysis costs,' he said.

Pharma lobby flags 'cumbersome' export rule, seeks change
Pharma lobby flags 'cumbersome' export rule, seeks change

Time of India

time2 hours ago

  • Time of India

Pharma lobby flags 'cumbersome' export rule, seeks change

New Delhi: A significant dip in exports has prompted pharma lobby groups to raise a demand for changing the centralised no-object certification (NOC) provision for drug exports . The provision, which requires pharma companies to seek an approval from the national regulatory agency of the importing country or an NOC from the Indian regulator for shipments, has resulted in a drop in exports and diverted trade to other nations, industry executives told ET. The issue was raised in a meeting held on Monday at Niti Aayog . "Pharma exports have suffered due to the mismatch or an anomaly in newly introduced regulatory standards by the drug regulatory authority of India," said a person who attended the meeting. In early March, the Drugs Controller General of India (DCGI) updated the export NOC checklist in the wake of events such as the controversy over a Mumbai-based drugmaker allegedly exporting addictive opioid drugs to West African nations such as Ghana and Nigeria. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like What the Market May Be Getting Wrong About Nvidia Seeking Alpha Read More Undo However, the stringent norms have started hurting exports, industry insiders said. "Taking approvals from different regulatory bodies has only made the whole process cumbersome," the person cited above said. He noted that medicines are manufactured depending on the patient population construct. Live Events For example, Dolo and other paracetamol tablets are approved in India in strengths of 325mg, 500 mg and 650 mg while in Nigeria, it's approved for a strength of 1,000 mg. To manufacture and export that, Indian drugmakers now require an NOC from Nigerian authorities. The lobby groups have urged the government to review the provision as, according to them, this would divert trade to other nations with less stringent regulations. "Such a condition has imposed an undue burden on Indian exporters, potentially stifling innovation and hindering the export of unapproved/banned products especially for the MSME pharmaceutical sector, which is under tremendous strain with respect to compliance to domestic and international guidelines and trade barriers (tariffs & non-tariffs),' an industry expert said on condition of anonymity. The Niti Aayog had called pharma experts to undertake an analysis of the current state of the industry, to understand the challenges faced by drugmakers and initiatives taken by them to ensure production of safe and effective products. Nikkhil K Masurkar, chief executive of Entod Pharmaceuticals, said the official think tank's call for a quality overhaul is both "timely and necessary." "While India has made remarkable strides as a global pharma hub, maintaining consistent, internationally acceptable quality standards remains a key challenge, especially among MSME companies," he said. "The root of the problem often lies not in intent, but in outdated infrastructure, fragmented regulatory enforcement, and insufficient technical training," Masurkar said. "To produce world-class medicines, we must invest in continuous quality improvement, digitalise compliance systems, and empower our MSME sector with both financial and technical support."

Gujarat scientist in US Developing Tech for effective treatment of brain diseases
Gujarat scientist in US Developing Tech for effective treatment of brain diseases

Time of India

time3 hours ago

  • Time of India

Gujarat scientist in US Developing Tech for effective treatment of brain diseases

Vadodara: A Gujarati scientist, native of Vadodara, is working on a technology that would deliver drugs in a larger quantity inside the brain. Dr Ishan Shah is a key member of the US team that has already got intellectual property (IP) rights for the research. "It's a long process, but this technology will help those suffering from any kind of brain diseases. Currently, only 0.1% of any drug given for brain ailments is able to enter the brain. It is a challenge to deliver the drugs inside the brain, which blocks a major quantity," explained Shah, who works for a private biotech company in Boston. "We are developing antibodies that will increase the quantity of drugs delivered inside the brain from 0.1% to 1%. This will increase the efficacy of drugs. We discovered a protein that captures the drug and puts it inside the brain. Our firm even got IP rights. Such an experiment is being undertaken for the first time," Shah told TOI over the phone from the US. The team's work has also been published by the Royal Society of Chemistry. Shah, 38, was also a member of the team working on an effective drug for Alzheimer's, which currently has no cure. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like New Launch by L&T – 3 & 4 BHKs Near Viviana L&T Evara Heights Enquire Now Undo "We are trying to find out the reason behind the spike of a certain protein that causes Alzheimer's. If we manage to ascertain the reason and control the accumulation of this protein, we will be able to delay the advancement of Alzheimer's. The drug is already in the trial stage," Shah, a senior scientist, added. He is the only Indian in the team working on this drug. A student of Bright School in Karelibaug, Shah completed his Bachelor's in Pharmacy from A R College of Pharmacy in Vidyanagar in 2009. He then pursued a Master's in Pharmacy at the University of Toledo in Ohio. "I wanted to stay in the field of drug discovery, so I pursued a PhD in pharmaceutical chemistry from the University of Kansas in 2011. Then I shifted to Boston, where I worked with a small firm before joining my current company in 2020," said Shah, who is settled in Boston with his wife, Kinjal.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store